

Press Release 7 September 2015

## **Infant Bacterial Therapeutics receives a further SEK 35 million funding from mother company BioGaia**

**To support Infant Bacterial Therapeutics (IBT) efforts to develop a drug to prevent the fatal disease necrotizing enterocolitis (NEC), BioGaia's board of directors has resolved to invest a further SEK 35 million in IBT.**

Previously, BioGaia decided to invest up to a total of SEK 47 million in IBT to conduct the early stages of the pharmaceutical development of IBP-9414 as a preventive therapy for NEC and to prepare for the start of the upcoming clinical trial.

IBT has carried out a new issue of 40,000 shares in which all shares have been subscribed for by BioGaia AB. BioGaia's total investment in IBT thus amounts to approximately SEK 82 million and its holding to 94.5 per cent.

As communicated earlier, IBT plans to start a study on the safety and tolerability of the drug candidate IBP-9414 in 2015. IBT has an estimated capital need for 2016 of an additional SEK 100 million.

Efforts to evaluate partnership opportunities and the possibility for a separate listing of IBT are continuing.

IBT's work is aimed at developing a unique orphan drug to prevent the fatal disease NEC. NEC kills approximately 3,700 European and 1,500 US infants per year. NEC has an unpredictable, spontaneous, and acute onset and is untreatable, except through major surgery. The long-term complications for infants who survive NEC vary, but include impairment such as short bowel syndrome, prolonged neonatal hospitalisation and adverse neurodevelopmental outcomes, including cerebral palsy, cognitive impairment, and visual and hearing impairment.

**For additional information please contact**

Peter Rothschild, President BioGaia: telephone +46 8 555 293 00  
Staffan Strömberg, President IBT, telephone: +46 8 410 145 55

**Infant Bacterial Therapeutics AB**

Gamla Brogatan 11, 111 20 Stockholm, Sweden  
Phone: +46 (0) 84 101 4555  
E-mail: [info@ibtherapeutics.com](mailto:info@ibtherapeutics.com)  
[www.ibtherapeutics.com](http://www.ibtherapeutics.com)